Parthenon Therapeutics Appoints Joseph Paul Eder, MD, as Chief Medical Officer
Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
- Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
- We are excited to welcome Dr. Joseph Paul Eder to Parthenon as Chief Medical Officer.
- His experience also extends to the pharmaceutical industry where he was Senior Medical Science Director & Global Clinical Medical Director, Hematology at AstraZeneca, PLC.
- Dr. Eder is Chief Medical Officer at Parthenon, bringing over 30 years of clinical experience at leading cancer research institutions as well as the pharmaceutical industry.